Home
Clinical Trials
Intraocular Pressure Immediat...

Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab

Last Updated: 2008-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-01-31

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will quantify the intraocular pressure elevation in the immediate time period following intravitreous injection. With more widespread use of intravitreous injections in patients that may require several injections per year, it is important to document the sudden increase in intraocular pressure, including the maximum intraocular pressure and the time required for the intraocular pressure to return to baseline. This data may be useful in stimulating additional studies to evaluate the long term ocular effects of repeated intravitreous injections.

We hypothesize that the intraocular pressure increases significantly following intravitreous injection and then returns to baseline during the initial thirty minutes following ranibizumab injection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

NCT01015495

Angioid Streaks

WITHDRAWN PHASE1/PHASE2

Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

NCT00749021

Retinal Pigment Epithelial Detachment

COMPLETED PHASE1

Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma

NCT01370135

Neovascular Glaucoma Rubeosis

COMPLETED NA

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

NCT00955630

Ocular Histoplasmosis Syndrome

UNKNOWN PHASE1/PHASE2

Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial

NCT00363168

Choroidal Neovascularization

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We will assess the trend of intraocular pressure immediately following intravitreal injection of ranibizumab 0.5 mg (0.05 mL) by taking serial intraocular pressure readings every five minutes for thirty minutes after injection. This study is a prospective descriptive data collection consisting of measuring intraocular pressure immediately following intraocular injection, and at 5, 10, 15, 20, 25, and 30 minutes following injection of ranibizumab 0.5 mg.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Choroidal Neovascularization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or Female Patients \>18 years of age
2. Patients will have documented choroidal neovascular membranes on fluorescein angiogram and/or optical coherence tomography
3. Requiring treatment or maintenance therapy for choroidal neovascular membrane
4. Able and willing to provide written informed consent